Skip to main content

Rheums Speak - RA Treatment Survey

Be sure to take todays new Survey on Changing Rheumatology Practice & Choices!!

RheumNow's August 2025 “Live Vote” surveys will examine Rheumatologist impressions, knowledge and practices over the last 20 years when treating rheumatoid arthritis.

The first survey on RA Treatment (7/28/2025) sheds light on evolving prescribing habits, use of biologics, and key frustrations in RA care.

From a single email invite (and social medial prompt) a total of 458 responses were collected from US and non-US Rheumatologists, fellows and advanced practice providers dedicated to rheumatology.  Worldwides responses included 195 (43%) from US and 228 (57%) from outside the US (from 34 countries).  Respondents were mostly male (62%), with most (45%) practicing for more than 20 years. 

Worldwide results are shown (US results shown in parentheses).

Key Findings from the RA Treatment Survey

  • Biologics tend to dominate therapeutic choices and may have been the most transformative advancement
    • 59% of respondents identified biologic agents as the greatest advancement in RA care in the last 20 years - even higher in US Rheums (72%).  Fewer viewed the greatest advance in the last 20 years to be methotrexate 33% (23% in the US) or JAK inhibitors 6% (2% in the US). 
  • Earlier Use of Biologics has become the Norm
    • A majority (57%) reported using biologics earlier than they did 20 years ago, reflecting a major shift in treatment philosophy. Nearly 20% indicated their confidence in biologics by knowing how and when to use these agents safely; and 6-9% indicated that all patients are on biologics or newer agents.
    • Over the last 20 years they are using MORE:
      • TNF inhibitors 43% (US 53%)
      • JAK inhibitors 21% (US - 24%)
      • Methotrexate 25% (US - 3%)
      • IL-6 inhibitors  5% (US - 9%)
    • Over the last 20 years they are using LESS:
      • Hydroxychloroquine 46% (US - 55%)
      • B cell inhibitors 14% (US - 18%)
      • T cell costimulation 25% (US - 9%)
    • Biologic choices have matured
      • Most clinicians are pivoting after a TNF inhibitor failure, with the majority switching to another mechanism of action (MOA) agent after either One 50% (US 40%) or Two 45% (US 59%) TNF Inhibitors. 
        • Only 3-5% of rheumatologists use other MOA biologics first.
      • After failing at least 1 biologic (e.g., TNFi), more are likely to choose another MOA drug (44%), as opposed to choice guided by insurance 19% US 33%), efficacy data 14% (12%) or safety concerns 12% (US 8%). 
    • Strong Expectations for Early Treatment Response with Biologics
      • Over 90% of respondents expect to see a clinical response to biologics within 3 months, with nearly 30% expecting improvement within 6 weeks—highlighting a sense of urgency with biologic treatments.
  • Hydroxychloroquine Use Has Declined Significantly
    • 46-55% of rheumatologists reported using less hydroxychloroquine over the past 20 years— the most significant decline among DMARDs.
  • Treatment Decisions in RA Care - Favors Swollen Joints Over Labs
    • The need for aggressive newer therapies is most influenced by the number of swollen joints, >39%, followed by radiographic erosions 31% and functional disability 18%. By contrast, only 8-12% indicate labs (seropositivity,ESR, CRP) influence aggressive prescribing.
  • Many Disappointments in RA Care
    • Rheums were equally split in what is most disappointing about RA care:
      • Lack of predictive biomarkers 26% (US - 23%)
      • Cost of care 22% (US - 32%) 
      • Unpredictable DMARD responses 21% (US - 22%)
      • Untimely referral 16% (US - 10%)
      • Overuse of steroids 15% (US - 14%)

Based on these findings, respondents suggest several needs in RA Treatment:

  • There is a need for more guidance on the earlier and targeted use of biologics, particularly non-TNF MOAs.
  • There is a desire for predictive biomarkers to guide treatment selection.
  • The use of biosimilars is a minority (5-9%) among prescribers. 

 

Advancedisappointing

 

LessMore

 

20yr changeTime to resp

 

 

This series of surveys was sponsored by Bristol Myers Squibb and will conclude with a Tuesday Nite Rheumatology Webinar, on August 26, 2025. 

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject
×